Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · The Lancet · 170 citations
https://doi.org/10.1016/s0140-6736(24)02551-0